Mesoblast Interview: The Best Adult Stem Cell Technology In The World?

CEO Silviu Itesu speaks on his company’s adult stem cell technology, particularly mesenchymal precursor cells, and the low-cost manufacturing capabilities that the technology implies. Itesu discusses development compound Revascor for use in congestive heart failure and details the latest Phase II results. In 60 patients the drug saw no adverse events and a 0% event rate (hospital visits, mortality) compared to 20% in a control group; the company is planning to initiate a 1500-patient Phase III study in the coming few months.

Following is a link to an interview with Mesoblast Chief Executive, Professor Silviu Itescu, and healthcare analyst and Forbes contributor, Avik Roy – [listen now]